Connect with us


Novartis to cut over 600 jobs amid global restructuring



The US will also remain a “key development hub with strong representation in our global program teams, responsible for advancing our medicines pipeline,” the spokesperson said.

According to Reuters, Novartis’ planned job cuts in development are separate from a broader restructuring initiative that could see as many as 8,000 jobs cut from its global workforce of 78,000.

Roche, another Swiss pharmaceutical leader, announced in February that it was eliminating 345 roles in production development.

“The success and sustainable growth of our company depends on our ability to recognize innovation proactively and early on, to adapt to change and to use our resources wisely,” a spokesperson for Roche said. “We expect Roche’s total workforce to remain stable in 2024.”

Have something to say about this story? Feel free to share your comments below.

Read the full article here